Reproductive Biotechnology: Advances, Clinical Applications, Ethical Considerations and Future Directions

Dimlong James Umaru[1], Vongfa Augusta Chinwendu[2], Mijinyawa Panu Shedrack[3], Pam John Choji[4], Gochuk Lashime Daniel[5], Dashe Bulus Damar[6]

[1] *Department of Pharmacy Technician, College of Health Technology, Pankshin, Plateau, Nigeria*

[2] *Department of Nutrition and Dietetics, College of Health Technology Zawan, Plateau, Nigeria*

[3] *Department of Human Anatomy, Plateau State University, Plateau, Nigeria*

[4, 5,6] *Department of Dental Technology, College of Health Technology Zawan, Plateau, Nigeria*

ABSTRACT

Reproductive biotechnology is a rapidly advancing multidisciplinary field integrating reproductive endocrinology, human embryology, genetics, molecular biology, cryobiology and assisted reproductive medicine to prevent, diagnose and manage infertility and preserve reproductive potential. Infertility affects approximately one in six people of reproductive age globally and represents an important reproductive-health, psychosocial and socioeconomic challenge (World Health Organization [WHO], 2025). Assisted reproductive technology (ART), particularly in vitro fertilization (IVF), has transformed infertility treatment by enabling controlled manipulation of oocytes, sperm and embryos outside the human body. Contemporary ART encompasses ovarian stimulation, follicular monitoring, final oocyte maturation, oocyte retrieval, conventional IVF or intra cytoplasmic sperm injection (ICSI), embryo culture, embryo selection, embryo transfer and cryopreservation. Additional technologies include assisted hatching, donor gametes, gestational-carrier arrangements and pre implantation genetic testing (PGT). Embryo verification has expanded fertility preservation and frozen embryo-transfer strategies, whereas PGT provides opportunities for identifying selected genetic and chromosomal abnormalities before embryo transfer. However, reproductive biotechnology presents clinical, ethical, economic and regulatory challenges, including ovarian hyper stimulation, treatment failure, multiple pregnancy, embryo disposition, genetic privacy, donor-related issues and unequal access. Current evidence also indicates that PGT-A should not be regarded as a universal screening procedure and that routine ICSI is not justified in the absence of male-factor infertility or previous fertilization failure (American Society for Reproductive Medicine [ASRM], 2024, 2026). Emerging artificial intelligence (AI), genomics and automated embryo-assessment technologies offer considerable potential but require rigorous clinical validation. This review examines the scientific principles, clinical applications, complications, ethical implications, limitations, recommendations and future directions of reproductive biotechnology, with particular attention to evidence-based and equitable fertility care.

KEYWORDS

Reproductive biotechnology, assisted reproductive technology, infertility, in vitro fertilization, intra cytoplasmic sperm injection, embryo cryopreservation, pre implantation genetic testing, reproductive medicine

I. INTRODUCTION

Reproductive biotechnology represents the application of biological sciences, medical technologies and laboratory techniques to understand, preserve, manipulate and improve human reproductive processes. It is inherently multidisciplinary and incorporates knowledge from human anatomy, reproductive physiology, endocrinology, embryology, genetics, molecular biology, cryobiology, reproductive medicine and bioethics. Its development has transformed the management of infertility from predominantly surgical and pharmacological approaches to sophisticated laboratory-based interventions capable of manipulating gametes and embryos before implantation.

The clinical significance of reproductive biotechnology is closely associated with the global burden of infertility. The WHO defines infertility as the failure to achieve pregnancy after 12 months or more of regular unprotected sexual intercourse and estimates that approximately one in six people of reproductive age experience infertility during their lifetime (WHO, 2025). Infertility may result from female reproductive disorders, male reproductive abnormalities, combined male and female factors or unexplained causes. The consequences extend beyond the inability to conceive and may include psychological distress, social stigma, relationship difficulties and substantial financial expenditure. The WHO's 2025 global guideline emphasizes that infertility should be addressed as an important component of reproductive health and that fertility services should become safer, more affordable, accessible and equitable (WHO, 2025).

Assisted reproductive technology constitutes one of the most important practical applications of reproductive biotechnology. ART involves the handling of human oocytes, sperm, embryos or reproductive tissues to establish pregnancy. The supplied University of Jos seminar identifies IVF, ICSI, embryo cryopreservation, donor gametes, assisted hatching and PGT among the principal contemporary approaches. These technologies have expanded reproductive possibilities for individuals with tubal infertility, male-factor infertility, ovulatory disorders, unexplained infertility, genetic disorders and fertility-threatening medical conditions.

IVF remains the central framework of ART. A conventional IVF cycle involves ovarian stimulation, follicular monitoring, final oocyte maturation, ultrasound-guided oocyte retrieval, laboratory fertilization, embryo culture, embryo selection and embryo transfer. Surplus embryos may be cryopreserved for subsequent use. Contemporary clinical practice emphasizes individualized ovarian stimulation and appropriate prevention of treatment-related complications. The European Society of Human Reproduction and Embryology (ESHRE) guideline on ovarian stimulation addresses pre-stimulation management, pituitary suppression, gonadotropin stimulation, monitoring, triggering of final oocyte maturation, luteal support and prevention of ovarian hyper stimulation syndrome (OHSS) (ESHRE, 2025).

Ovarian stimulation is designed to promote the development of multiple follicles, thereby increasing the number of mature oocytes available for fertilization. Gonadotropins are commonly administered to stimulate follicular recruitment and development, while GnRH agonists or antagonists can be used to control premature luteinizing hormone activity. Follicular growth is monitored primarily through ultrasound, with hormonal assessment used where clinically indicated. Individualization is important because inadequate stimulation may result in poor oocyte yield, whereas excessive ovarian response can increase the risk of OHSS.

Final oocyte maturation is induced using an appropriate hormonal trigger, after which oocyte retrieval is performed under ultrasound guidance. Follicular fluid is aspirated and examined microscopically to identify recovered oocytes. Successful oocyte retrieval depends on appropriate follicular development, trigger timing, technical competence and laboratory coordination.

Fertilization can be achieved through conventional IVF or ICSI. Conventional IVF places prepared sperm in proximity to mature oocytes, allowing fertilization to occur without direct sperm injection. ICSI involves the selection of an individual sperm and its direct injection into the oocyte cytoplasm. ICSI has particular value in selected cases of male-factor infertility and previous fertilization failure. However, contemporary evidence does not support routine ICSI for all IVF cycles in patients without male-factor infertility. ASRM's 2026 committee opinion concluded that routine ICSI in the absence of male-factor infertility or previous fertilization failure does not improve live-birth outcomes (ASRM, 2026).

Following fertilization, embryos undergo cleavage and progressive differentiation through the morula and blastocyst stages. Embryos are maintained in specialized culture media under tightly controlled temperature and atmospheric conditions. Embryologists assess developmental progression and morphological characteristics before determining whether embryos should be transferred or cryopreserved.

Embryo transfer involves introducing a selected embryo into the uterine cavity using a thin catheter passed through the cervix. Progesterone support may be provided to optimize endometrial receptivity. Appropriate selection of the number of embryos for transfer is important because multiple embryo transfer increases the risk of multiple pregnancy and associated maternal and neonatal complications.

Cryopreservation is another major component of reproductive biotechnology. Modern verification uses ultra-rapid cooling to minimize intracellular ice formation and has become a predominant method for embryo preservation. Embryos can be stored in liquid nitrogen and subsequently warmed before transfer. Cryopreservation allows surplus embryos to be preserved, facilitates subsequent frozen embryo transfer and contributes to fertility-preservation strategies.

Reproductive biotechnology has also expanded into genetic assessment. PGT permits the genetic evaluation of embryos before transfer. PGT-A is used to assess chromosomal aneuploidy, PGT-M targets selected monogenic disorders and PGT-SR evaluates structural chromosomal rearrangements. Although PGT provides important opportunities for couples at risk of specific genetic disorders, the routine use of PGT-A for all IVF patients is not supported by current evidence. ASRM (2024) concluded that the value of PGT-A as a universal screening test has not been demonstrated.

Third-party reproduction further demonstrates the expanding scope of reproductive biotechnology. Donor sperm, donor oocytes, donor embryos and gestational-carrier arrangements can provide reproductive options for patients who cannot conceive using their own gametes. Such programmes require donor screening, informed consent, genetic assessment, confidentiality and appropriate infectious-disease safeguards.

Despite its benefits, reproductive biotechnology is associated with complications and ethical challenges. Potential clinical problems include poor ovarian response, excessive ovarian response, OHSS, premature ovulation, unsuccessful oocyte retrieval, failed fertilization and

failed embryo development. Ethical concerns include embryo selection, embryo disposition, genetic privacy, donor identity, reproductive autonomy, commercialization and equitable access.

Accordingly, reproductive biotechnology should not be considered solely a technological enterprise. Its appropriate development requires integration of scientific evidence, clinical expertise, laboratory quality management, ethical governance, patient counselling and public-health policy. This review therefore examines the major technologies, clinical procedures, complications, ethical considerations, limitations and future directions of reproductive biotechnology.

II. ASSISTED REPRODUCTIVE TECHNOLOGY: SCIENTIFIC AND CLINICAL FRAMEWORK

ART involves procedures in which oocytes, sperm or embryos are manipulated to establish pregnancy. IVF is the central ART procedure and involves coordinated endocrine stimulation and laboratory embryology. A typical treatment cycle progresses through ovarian stimulation, follicular monitoring, final oocyte maturation, oocyte retrieval, fertilization, embryo culture, embryo selection and transfer or cryopreservation.

The effectiveness of IVF depends on interactions among ovarian response, oocyte competence, sperm quality, fertilization, embryo development, endometrial receptivity and implantation. Consequently, an apparently successful laboratory procedure does not necessarily result in pregnancy or live birth.

The WHO recommends a progressive approach to infertility treatment in which management is guided by the cause of infertility, clinical findings, patient preferences, available resources and evidence concerning effectiveness (WHO, 2025).

III. OVARIAN STIMULATION AND CONTROL OF OVULATION

Controlled ovarian stimulation is designed to recruit multiple follicles and increase the probability of obtaining mature oocytes. Gonadotropins provide follicle-stimulating activity, while GnRH agonists or antagonists can suppress premature ovulation. Follicular development is monitored using tran’s vaginal ultrasonography, with serum estradiol measurements used where appropriate.

The ovarian response varies substantially between patients. Factors including age, ovarian reserve, previous response, body characteristics and reproductive history may influence the response to stimulation. Excessive response can increase OHSS risk, whereas inadequate response may reduce the number of available oocytes.

The updated ESHRE guideline emphasizes individualized ovarian stimulation, appropriate monitoring, triggering of final oocyte maturation and prevention of OHSS (ESHRE, 2025). Therefore, stimulation should be regarded as a carefully controlled physiological intervention rather than simply a method of maximizing the number of oocytes.

IV. FINAL OOCYTE MATURATION AND OOCYTE RETRIEVAL

Final oocyte maturation is induced using a hormonal trigger such as human chorionic gonadotropin or a GnRH agonist, depending on the clinical protocol. Retrieval is then performed within the appropriate time interval using transvaginal ultrasound-guided follicular aspiration. The recovered follicular fluid is examined by embryologists for identification of oocytes.

The procedure requires coordination between the reproductive clinician, anaesthetic team, embryologist and nursing personnel. Errors in trigger timing, retrieval technique or laboratory identification can compromise treatment outcomes. Consequently, standardized protocols and clear communication between the clinical and embryology teams are essential.

V. FERTILIZATION: CONVENTIONAL IVF AND ICSI

Conventional IVF permits sperm and oocyte interaction under controlled laboratory conditions. In contrast, ICSI involves direct injection of a selected sperm into a mature oocyte.

ICSI represents an important advancement for male-factor infertility, including severe abnormalities in sperm concentration, motility or morphology and selected cases of previous fertilization failure. However, increasing fertilization rates does not necessarily translate into increased live-birth rates.

The most recent ASRM guidance states that routine ICSI is not recommended for non-male-factor infertility because available evidence does not demonstrate improved live-birth outcomes in this population (ASRM, 2026). This distinction is particularly important for evidence-based practice because the technical sophistication of ICSI should not be confused with superior clinical effectiveness.

ICSI may nevertheless remain appropriate in selected situations, including previous failed or poor fertilization with conventional IVF, certain male-factor conditions and selected PGT-M cycles where minimizing contamination is clinically important (ASRM, 2026).

VI. EMBRYO CULTURE AND DEVELOPMENT

Following fertilization, the zygote undergoes cleavage divisions and progresses through increasingly complex developmental stages. The major stages include the cleavage-stage embryo, morula and blastocyst.

Embryo culture requires precise control of temperature, pH, gas concentrations, osmolality and culture-medium composition. Embryology laboratories must therefore maintain stable environmental conditions and implement rigorous quality-control procedures.

Embryo morphology remains an important component of embryo assessment. However, morphology alone cannot completely determine chromosomal status or developmental competence. Consequently, reproductive biotechnology has increasingly incorporated time-lapse imaging, molecular testing and computational methods.

VII. EMBRYO SELECTION AND TRANSFER

Embryo selection may incorporate developmental rate, morphology and, where clinically indicated, genetic information. Embryo transfer is performed using a catheter introduced through the cervix into the uterine cavity.

The principal objective should be achievement of a healthy singleton pregnancy rather than simply increasing the number of embryos transferred. Multiple pregnancy increases maternal and neonatal risks. Therefore, embryo-transfer strategies should be individualized and aligned with current professional guidance.

Progesterone is frequently used to support endometrial receptivity, although the precise protocol depends on the type of embryo-transfer cycle and underlying clinical circumstances.

VIII. EMBRYO CRYOPRESERVATION

Embryo cryopreservation enables embryos to be stored for later transfer. Vitrification involves ultra-rapid cooling and has become an established method for preserving embryos because it minimizes ice-crystal formation.

Cryopreservation provides several clinical benefits. Surplus embryos generated during an IVF cycle can be stored rather than discarded, patients can undergo subsequent frozen embryo transfer, and embryos can be preserved before treatments that may compromise reproductive potential.

However, cryopreservation programmes require reliable cryogenic storage, accurate specimen identification and emergency-response systems. Failure in any component of the cryostorage system can have irreversible consequences for patients.

IX. MICROMANIPULATION AND ASSISTED HATCHING

Micromanipulation refers to specialized laboratory procedures performed on oocytes or embryos using microscopic equipment. ICSI represents the best-established micromanipulation procedure. Assisted hatching involves controlled modification of the zona pellucida with the intention of facilitating embryo interaction with the endometrium.

Because micromanipulation involves direct physical intervention with gametes or embryos, technical precision and embryologist competence are essential. Such procedures should be performed only when supported by appropriate clinical indications and laboratory expertise.

X. PRE IMPLANTATION GENETIC TESTING

PGT represents a major intersection between reproductive biotechnology and genomic medicine. PGT-M can be used for selected monogenic disorders, PGT-SR for structural chromosomal rearrangements and PGT-A for assessment of chromosomal aneuploidy.

PGT can be particularly valuable for couples with a known risk of transmitting serious genetic disease. However, genetic testing is not synonymous with genetic certainty. Embryo biopsy samples a limited number of cells, while mosaicism and technical limitations can complicate interpretation.

The evidence concerning PGT-A requires particular caution. ASRM (2024) concluded that the value of PGT-A as a routine screening test for all IVF patients has not been demonstrated. Recent multicentre randomized evidence has not established universal superiority over conventional IVF in terms of cumulative reproductive outcomes.

Therefore, PGT-A should be considered selectively rather than automatically incorporated into every IVF cycle.

XI. DONOR GAMETES AND THIRD-PARTY REPRODUCTION

Third-party reproduction involves reproductive contributions from individuals other than the intended parent or parents. This may involve donor sperm, donor oocytes, donor embryos or gestational carriers.

Donor programmes require careful screening for infectious diseases, genetic conditions and relevant medical factors. Ethical and legal frameworks must also address informed consent, confidentiality, donor identity, record keeping and the interests of donor-conceived offspring.

In addition, recipient preparation must be appropriately synchronized with embryo development. These procedures demonstrate that reproductive biotechnology extends beyond laboratory manipulation into complex social, legal and ethical domains.

XII. COMPLICATIONS AND SAFETY CONSIDERATIONS

ART is generally established as a major component of infertility care, but treatment may produce clinical complications. Ovarian stimulation may result in inadequate or excessive ovarian response. OHSS remains an important complication of excessive ovarian stimulation. Other potential problems include premature ovulation, failed oocyte retrieval, failed fertilization, arrested embryo development and inability to proceed with embryo transfer.

Cycle cancellation may be considered where the anticipated benefit is insufficient or where patient safety is compromised. Counselling before treatment should therefore include realistic expectations regarding the possibility of cancellation and treatment failure.

Multiple pregnancy represents another important ART-related concern. Transfer of multiple embryos may increase pregnancy rates in some circumstances but can substantially increase maternal and neonatal risks. Consequently, treatment strategies should prioritize healthy singleton outcomes.

XIII. ETHICAL AND SOCIAL CONSIDERATIONS

The rapid development of reproductive biotechnology has generated ethical questions that cannot be resolved solely through laboratory science. Embryo selection raises questions concerning reproductive autonomy, embryo disposition and the moral status of embryos. PGT raises concerns regarding genetic privacy, discrimination and the possibility of selecting embryos according to increasingly broad characteristics.

Donor reproduction creates additional concerns involving donor identity, confidentiality, informed consent and the rights and interests of donor-conceived children.

Ethical governance should therefore include clinicians, embryologists, geneticists, bioethicists, policymakers, patients and members of the public. Ethical oversight should evolve alongside technological development.

XIV. EQUITY AND PUBLIC-HEALTH IMPLICATIONS

Infertility should be considered an important public-health issue because its effects extend beyond individual reproductive capacity. The WHO estimates that infertility affects approximately one in six people of reproductive age and identifies significant inequalities in access to diagnosis and treatment (WHO, 2025).

The financial cost of ART represents a major barrier. In many settings, fertility treatment is largely financed directly by patients, creating substantial financial hardship. The WHO 2025 guideline specifically seeks to support safer, fairer and more affordable fertility care and encourages countries to incorporate infertility services into national health strategies.

For Nigeria and other low- and middle-income countries, challenges include limited specialist services, inadequate laboratory infrastructure, high treatment costs, limited insurance coverage and insufficient national ART data. Addressing these barriers requires health-system investment rather than reliance solely on technological expansion.

XV. EMERGING TECHNOLOGIES AND FUTURE DIRECTIONS

The future of reproductive biotechnology is likely to involve increasing integration of genomics, automation, advanced imaging, molecular diagnostics and artificial intelligence. AI has potential applications in embryo assessment, image analysis, prediction of embryo developmental potential and individualized treatment. However, technological performance must be distinguished from demonstrated clinical benefit. An algorithm that accurately classifies embryo images does not necessarily improve live-birth outcomes.

Consequently, AI systems should undergo prospective and multicentre validation using diverse patient populations. Issues of algorithmic bias, explain ability, cyber security, patient consent and data governance must also be addressed. Genomics and molecular technologies may similarly provide new approaches to understanding embryo competence and reproductive disease. However, these technologies should be introduced only when their analytical validity, clinical validity and clinical utility have been sufficiently demonstrated.

XVI. LIMITATIONS OF REPRODUCTIVE BIOTECHNOLOGY AND CURRENT EVIDENCE

Several limitations affect both the practice and scientific evaluation of reproductive biotechnology.

First, reproductive outcomes are strongly influenced by patient characteristics, including age, ovarian reserve, sperm quality, infertility diagnosis and previous treatment history. Therefore, results from one patient population cannot necessarily be generalized to another.

Second, some reproductive technologies have been adopted more rapidly than the evidence supporting their routine clinical use. PGT-A is a prominent example. Although technically sophisticated, current evidence does not demonstrate that routine PGT-A improves outcomes for all IVF patients (ASRM, 2024).

Third, ICSI is sometimes used beyond its strongest evidence base. Current ASRM guidance indicates that routine ICSI in non-male-factor infertility does not improve live-birth outcomes (ASRM, 2026).

Fourth, emerging AI-based approaches remain limited by retrospective datasets, differences between laboratories and inadequate external validation. Future research must therefore prioritize clinically meaningful endpoints.

Fifth, the cost and infrastructure requirements of ART restrict accessibility, especially in low-resource environments. Consequently, technologies developed in high-income countries may not be immediately transferable to countries with limited laboratory infrastructure.

Finally, long-term data regarding some emerging technologies and their effects on ART-conceived offspring remain incomplete. Continued longitudinal surveillance is therefore required.

XVII. CONCLUSION

Reproductive biotechnology has transformed the management of infertility by integrating reproductive endocrinology, embryology, genetics, cryobiology and advanced laboratory medicine. IVF remains the principal framework of ART, while ICSI, embryo culture, cryopreservation, micromanipulation, and PGT and donor reproduction have expanded reproductive options for individuals and couples experiencing infertility.

However, reproductive biotechnology should not be assessed solely by its technological sophistication. Its value must be determined by clinical effectiveness, safety, reproductive outcomes, affordability, ethical acceptability and patient-centeredness. Current evidence demonstrates that some technologies should be applied selectively rather than universally. In particular, routine ICSI is not supported for non-male-factor infertility, while PGT-A should not be regarded as a universal screening test (ASRM, 2024, 2026).

The WHO 2025 infertility guideline provides an important framework for moving fertility care toward greater accessibility, affordability, quality and equity. For Nigeria, this requires investment in ART infrastructure, specialist training, regulation, research, national data systems and mechanisms that reduce financial barriers.

Future reproductive biotechnology will probably involve greater integration of genomics, AI, automation, advanced embryo assessment and fertility preservation. Nevertheless, emerging technologies require rigorous prospective validation and ethical governance before widespread implementation.

Ultimately, the goal of reproductive biotechnology should extend beyond achieving pregnancy to achieving safe, healthy, affordable, ethically responsible and equitable reproductive outcomes.

RECOMMENDATIONS

A. Individualized infertility management

Infertility evaluation and treatment should be individualized according to the underlying cause, patient age, reproductive history, ovarian reserve, semen parameters, previous treatment response and patient preferences. Treatment should progress according to evidence-based clinical indications rather than technological availability.

B. Strengthening ART laboratory quality assurance

Fertility centers should implement standardized operating procedures for oocyte handling, sperm preparation, fertilization, embryo culture, embryo assessment, cryopreservation and embryo transfer. Continuous quality monitoring and professional competency assessment should be mandatory.

C. Rational use of ICSI

ICSI should be used primarily where clinically indicated, particularly in male-factor infertility and previous poor or failed fertilization with conventional IVF. Routine ICSI should not be used merely because it is technologically more sophisticated (ASRM, 2026).

D. Selective use of PGT

PGT should be performed when there is a clearly defined clinical indication and appropriate genetic counselling. PGT-A should not be regarded as a universal requirement for IVF because current evidence does not demonstrate universal improvement in reproductive outcomes (ASRM, 2024).

E. Prevention of treatment complications

Ovarian stimulation should be individualized, monitored carefully and designed to minimize OHSS and other preventable complications. The updated ESHRE guideline should inform ovarian stimulation protocols and safety procedures (ESHRE, 2025).

F. Promotion of safe embryo-transfer practices

Fertility centers should adopt embryo-transfer policies that minimize avoidable multiple pregnancy and prioritize healthy singleton outcomes.

G. Strengthening genetic counselling

Genetic counselling should be integrated into PGT and donor-reproduction programmers. Patients should understand the purpose, benefits, limitations and possible consequences of genetic testing before making treatment decisions.

H. Improving equitable access

Governments and healthcare institutions should develop strategies for reducing financial barriers to infertility diagnosis and treatment. The WHO recommends integration of fertility care into national health strategies and financing systems to reduce inequalities (WHO, 2025).

I. Developing reproductive biotechnology capacity in Nigeria

Nigeria should invest in modern embryology laboratories, cryopreservation facilities, reproductive endocrinology services, genetic counselling, specialist embryology training and reproductive-health research.

J. Establishing national ART regulation

National regulatory authorities should establish standards for fertility clinics, gamete donation, embryo storage, PGT, donor screening, embryo disposition and third-party reproduction.

K. Developing a national ART registry

A national ART registry should capture treatment cycles, fertilization rates, embryo development, transfer outcomes, pregnancy, miscarriage, live birth, multiple pregnancy and neonatal outcomes. Such a registry would strengthen clinical monitoring and health-policy development.

L. Responsible adoption of artificial intelligence

AI-assisted reproductive technologies should be introduced gradually following prospective clinical validation. AI should complement rather than replace qualified embryologists and reproductive clinicians.

M. Strengthening psychosocial support

Infertility services should incorporate psychological and psychosocial support because infertility can cause anxiety, depression, social isolation and financial distress. WHO emphasizes the importance of people-centered and psychosocially supportive fertility care (WHO, 2025?)

N. Promoting multidisciplinary research

Research should integrate reproductive medicine, human anatomy, embryology, genetics, molecular biology, bioinformatics, cryobiology and public health. Particular attention should be given to embryo competence, implantation, reproductive ageing, fertility preservation and long-term outcomes of ART-conceived offspring.

O. Overall recommendation

The overarching recommendation is that reproductive biotechnology should be implemented within an evidence-based, patient-centered, ethically regulated and equitable reproductive-

health framework. Technological sophistication should not be regarded as a substitute for demonstrated clinical effectiveness.

REFERENCES

[1] American Society for Reproductive Medicine. (2024). the use of pre implantation genetic testing for aneuploidy: A committee opinion. Fertility and Sterility, 122(3), 421–434. ASRM committee opinion on PGT-A

[2] American Society for Reproductive Medicine. (2026). Intra cytoplasmic sperm injection for nonmale factor indications: A committee opinion.

[3] European Society of Human Reproduction and Embryology. (2025). ESHRE guideline on ovarian stimulation for IVF/ICSI.

[4] Society for Assisted Reproductive Technology. (2026). ART: Step-by-step guide. SART ART step-by-step guide

[5] Society for Assisted Reproductive Technology. (2026). Micromanipulation. SART micromanipulation information

[6] University of Jos, Department of Human Anatomy. (n.d.). Postgraduate lecture series: Reproductive biotechnology [Lecture material].

[7] World Health Organization. (2025). Guideline for the prevention, diagnosis and treatment of infertility. World Health Organization.

[8] World Health Organization. (2025). Guideline for the prevention, diagnosis and treatment of infertility: Summary of recommendations. World Health Organization. WHO summary of infertility recommendations

[9] World Health Organization. (2025, November 28). WHO issues first global guideline on infertility?